[1] Sengoku R. Aging and Alzheimer’s disease pathology[J]. Neuropathology, 2020,40(1):22-29.
[2] Hanseeuw BJ, Scott MR, Sikkes S, et al. Evolution of anosognosia in alzheimer’s disease and its relationship to amyloid[J]. Ann Neurol, 2020,87(2):267-280.
[3] Schubert D. Glucose metabolism and Alzheimer’s disease[J]. Ageing Res Rev, 2005,4(2):240-257.
[4] Cho S, Lee H, Seo J. Impact of genetic risk factors for Alzheimer’s disease on brain glucose metabolism[J]. Mol Neurobiol, 2021,58(6):2608-2626.
[5] Chornenkyy Y, Wang WX, Wei A, et al. Alzheimer’s disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline[J]. Brain Pathol, 2019,29(1):3-17.
[6] Pilipenko V, Narbute K, Beitnere U, et al. Very low doses of muscimol and baclofen ameliorate cognitive deficits and regulate protein expression in the brain of a rat model of streptozocin-induced Alzheimer’s disease[J]. Eur J Pharmacol, 2018,818:381-399.
[7]Wang Q, Fan WJ, Sun YZh, et al. Kinesin1-mediated neuronal axoplasmic transport disorder in cerebral cortex of amyloid precursor protein/presenilin-1 transgenic mice[J]. Acta Anatomica Sinica, 2018,49(2):158-165. (in Chinese)
王倩, 范文娟, 孙仪征, 等. 淀粉样蛋白前体/早老素1转基因小鼠大脑皮质内kinesin1介导的神经元轴浆运输障碍[J]. 解剖学报, 2018,49(2):158-165.
[8] Steinman J, Sun HS, Feng ZP. Microvascular alterations in Alzheimer’s Disease[J]. Front Cell Neurosci, 2020,14:618986.
[9] Barbagallo M, Dominguez LJ. Type 2 diabetes mellitus and Alzheimer’s disease[J]. World J Diabetes, 2014,5(6):889-893.
[10] Pereira JD, Fraga VG, Santos ALM, et al. Alzheimer’s disease and type 2 diabetes mellitus: A systematic review of proteomic studies[J]. J Neurochem, 2020, 156(6): 753-776.
[11] Tumminia A, Vinciguerra F, Parisi M, et al. Type 2 diabetes mellitus and Alzheimer’s disease: role of insulin signalling and therapeutic implications[J]. Int J Mol Sci, 2018,19(11): 3306.
[12] van der Kant R, Goldstein L, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease[J]. Nat Rev Neurosci, 2020,21(1):21-35.
[13] Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics[J]. Acta Neuropathol, 2020,140(4):417-447.
[14] Malkki H. Alzheimer disease: Insulin resistance could be linked to risk of AD via reduced glucose uptake[J]. Nat Rev Neurol, 2015,11(9):485.
[15] Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-the disregarded partner of Alzheimer’s disease[J]. Alzheimers Dement, 2019,15(1):158-167.
[16] Reilly AM, Tsai AP, Lin PB, et al. Metabolic defects caused by high-fat diet modify disease risk through inflammatory and amyloidogenic pathways in a mouse model of alzheimer’s disease[J]. Nutrients, 2020,12(10):2977.
[17] Bracko O, Vinarcsik LK, Cruz Hernández JC, et al. High fat diet worsens Alzheimer’s disease-related behavioral abnormalities and neuropathology in APP/PS1 mice, but not by synergistically decreasing cerebral blood flow[J]. Sci Rep, 2020,10(1):9884.
[18] Nizari S, Carare RO, Hawkes CA. Increased Aβ pathology in aged Tg2576 mice born to mothers fed a high fat diet[J]. Sci Rep, 2016,6:21981.
[19] Cai ZhY, Zhao B. Molecular Biology of Alzheimer’s Disease[M]. Beijing: Science Press, 2016: 159-190.
蔡志友, 赵斌. 阿尔茨海默病分子生物学[M]. 北京: 科学出版社, 2016: 159-190.
[20] Schultz N, Br ?nnstr?m K, Byman E, et al. Amyloid-beta 1-40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro[J]. Aging Cell, 2018,17(3):e12728.
[21] Maesako M, Uemura K, Kuzuya A, et al. Presenilin regulates insulin signaling via a gamma-secretase-independent mechanism[J]. J Biol Chem, 2011,286(28):25309-25316.
[22] Beroun A, Mitra S, Michaluk P, et al. MMPs in learning and memory and neuropsychiatric disorders[J]. Cell Mol Life Sci, 2019,76(16):3207-3228.
[23] Rivera S, García-González L, Khrestchatisky M, et al. Metalloproteinases and their tissue inhibitors in Alzheimer’s disease and other neurodegenerative disorders[J]. Cell Mol Life Sci, 2019,76(16):3167-3191.
[24] Bruno MA, Mufson EJ, Wuu J, et al. Increased matrix metalloproteinase 9 activity in mild cognitive impairment[J]. J Neuropathol Exp Neurol, 2009,68(12):1309-1318.
|